scholarly journals Prognostic values of high blood pressure duringpregnancy

2008 ◽  
Vol 14 (1) ◽  
pp. 22-26 ◽  
Author(s):  
E. Baranova ◽  
O. Bolshakova
Keyword(s):  
Blood Pressure ◽  
Risk Factor ◽  
Cardiovascular Risk ◽  
Cardiovascular Diseases ◽  
Arterial Hypertension ◽  
High Blood Pressure ◽  
Young Women ◽  
Additional Risk ◽  
Hypertension In Pregnancy ◽  
In Pregnancy

Arterial hypertension in pregnancy is now believed to be a risk factor for future maternal cardiovascular diseases. Despite the low immediate cardiovascular risk in a population of young women, a pregnancy complicated with hypertension carries a significant additional risk of future disease.

scholarly journals A CASE STUDY ON ESSENTIAL HYPERTENSION MANAGING THROUGH AYURVEDA W.S.R. RAKTAGATA VYAN VAISHAMYA

2021 ◽  
Vol p5 (4) ◽  
pp. 2965-2968
Author(s):  
Ruhi Zahir ◽  
Iqbal Khan
Keyword(s):  
Blood Pressure ◽  
Renal Failure ◽  
Risk Factor ◽  
Essential Hypertension ◽  
Cardiovascular Diseases ◽  
High Blood Pressure ◽  
Direct Reference ◽  
Major Risk Factor ◽  
End Stage

Essential hypertension is high blood pressure that doesn't have any known etiopathology. Most of sufferers (85%) are asymptomatic and as per available reports, in more than 95% cases of hypertension under lying cause is not found. It is estimated that 600 million people are affected worldwide. Hypertension is a major risk factor for the development of cardiovascular diseases (CVD). Its impact is greatest on stroke, MI and end stage is renal failure as it’s known as a Silent Killer. Hence there is no direct reference of hypertension in Ayurvedic classics by name as well as by its path physiological views. Many works have been carried out on hypertension to evaluate the perfect diagnosis and mode of treatment on the basis of Different nomenclatures also have been adopted by Ayurveda experts like Raktagata Vata, Raktagata Vyana Vaisamya, Uccha Rakta Chapa, Raktavrita Vata, Siragata Vata etc. Keywords: Essential hypertension, Raktagata Vyana Vaisamya, Uccha Rakta Chapa, Cardiovascular diseases, Silent Killer.

Obesity-associated cardiovascular risk in women: hypertension and heart failure

2021 ◽  
Vol 135 (12) ◽  
pp. 1523-1544
Author(s):  
Jessica L. Faulkner
Keyword(s):  
Heart Failure ◽  
Risk Factor ◽  
Cardiovascular Risk ◽  
Cardiovascular Diseases ◽  
Cardiovascular Event ◽  
African Ancestry ◽  
Obese Women ◽  
Prevalence Of Obesity ◽  
Female Specific ◽  
In Pregnancy

Abstract The pathogenesis of obesity-associated cardiovascular diseases begins long prior to the presentation of a cardiovascular event. In both men and women, cardiovascular events, and their associated hospitalizations and mortality, are often clinically predisposed by the presentation of a chronic cardiovascular risk factor. Obesity increases the risk of cardiovascular diseases in both sexes, however, the clinical prevalence of obesity, as well as its contribution to crucial cardiovascular risk factors is dependent on sex. The mechanisms via which obesity leads to cardiovascular risk is also discrepant in women between their premenopausal, pregnancy and postmenopausal phases of life. Emerging data indicate that at all reproductive statuses and ages, the presentation of a cardiovascular event in obese women is strongly associated with hypertension and its subsequent chronic risk factor, heart failure with preserved ejection fraction (HFpEF). In addition, emerging evidence indicates that obesity increases the risk of both hypertension and heart failure in pregnancy. This review will summarize clinical and experimental data on the female-specific prevalence and mechanisms of hypertension and heart failure in women across reproductive stages and highlight the particular risks in pregnancy as well as emerging data in a high-risk ethnicity in women of African ancestry (AA).

scholarly journals New guidelines, and a new hypertensive population How to select women for menopausal hormone therapy

2018 ◽  
Vol 64 (1) ◽  
pp. 7-11
Author(s):  
José Pacheco-Romero
Keyword(s):  
Risk Factors ◽  
Blood Pressure ◽  
Cardiovascular Diseases ◽  
Arterial Hypertension ◽  
Hormone Therapy ◽  
High Blood Pressure ◽  
Hypertensive Population ◽  
Global Age ◽  
New Guidelines ◽  
Detection Evaluation

The 2017 ACC/AHA/AAPA/ABC/ACPM/ AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults published in November 2017(1) designates new categories of blood pressure in adults: Normal <120/140/>90 mm Hg. A previous report based on blood pressure readings in 19.1 million adults pooled from 1 479 studies found that the global age-standardized prevalence of raised blood pressure was 24.1% (21.4–27.1) in men and 20.1% (17.8–22.5) in women in 2015(2). The Peruvian Tornasol II study on Risk Factors for Cardiovascular Diseases reported in 2011 a prevalence of 27.3% for arterial hypertension(3), showing an increase compared to the previous value of 23.7% in 2006(4).

scholarly journals High blood pressure in pregnancy // Hipertenzija u trudnoći

2018 ◽  
Vol 5 (1) ◽  
pp. 28
Author(s):  
Marijana Bucalo ◽  
Anastasija Stojšić Milosavljević ◽  
Bojana Babin
Keyword(s):  
Blood Pressure ◽  
Literature Review ◽  
High Blood Pressure ◽  
Gestational Hypertension ◽  
Morbidity And Mortality ◽  
Significant Problem ◽  
Hypertension In Pregnancy ◽  
Gynecology And Obstetrics ◽  
Increased Risk ◽  
In Pregnancy

High blood pressure in pregnancy is a significant problem and has long been causing the attention of perinatologists. Hypertensive disorders in pregnancy are the leading cause of morbidity and mortality of mothers and fetuses. About 8% of pregnancies complicate high blood pressure. It is estimated that 192 women die daily due to hypertensive complications during pregnancy. Hypertension in pregnancy is not a single entity but it includes: pre-existing hypertension; gestational hypertension; pre-pregnancy existing hypertension complicated by gestational hypertension with proteinuria; prenatally unclassified hypertension. The aim of this paper is to point to the problem of hypertension in pregnancy and the importance of its early detection.It’s a literature review. The literature review period is from 2003-2013. The literature review was carried out in the Hinari, Pubmed and Google Scholar databases.A total of 50 scientific and professional papers in English and Serbian have been examined, of which work is included. 17. By reviewing the summary of each paper, all articles that did not report hypertension in pregnancy were excluded. Through research that was conducted, it was concluded that pregnancy is a significant problem in pregnancy and is therefore the leading cause of morbidity and mortality of both mothers and fetuses. However, the decision to introduce antihypertensive therapy and the choice of an adequate drug during pregnancy should be based on the assessment of the benefits and risks for each pregnant woman individually. Thus, the role of the health care nurse in gynecology and obstetrics has the primary goal and task to preserve and improve the health of women through a series of preventive-promotional activities, all of which are covered through primary, secondary, and tertiary prevention.A literature review lists the risk factors that can cause hypertension in pregnancy, including: age of the patient - under 20 and over 35 years, vascular and renal pathology, gestational diabetes, obesity or malnutrition, pheochromocytoma, systemic lupus, poor living conditions, there is and increased risk in first-born patients. Women who have been hypertensive during their first pregnancy have a higher risk of subsequent pregnancy.

Effects of flavonoids in experimental models of arterial hypertension

2021 ◽  
Vol 21 ◽  
Author(s):  
Noemi M. Atucha ◽  
Paola Romecín ◽  
Felix Vargas ◽  
Joaquin García-Estañ
Keyword(s):  
Blood Pressure ◽  
Risk Factor ◽  
Cardiovascular Diseases ◽  
Arterial Hypertension ◽  
Cardiovascular System ◽  
Human Disease ◽  
Epidemiological Studies ◽  
Experimental Models ◽  
Point Of View ◽  
The Many

: Flavonoids are a class of substances of a vegetal origin with many interesting actions from the point of view of human disease. Interest in flavonoids in the diet has increased in recent years due to the publication of basic, clinical and epidemiological studies that have shown a whole array of salutory effects related to intake of flavonols and flavones as well as a lower morbility and mortality of cardiovascular diseases. Since arterial hypertension is the most common modifiable risk factor for cardiovascular diseases, this review will focus mainly on the effects of flavonoids on the cardiovascular system with relation to the elevation of blood pressure. Its antihypertensive effects as well as the many investigations performed in experimental models of arterial hypertension are reviewed in this mini-review.

Chronic exogenous hyperinsulinaemia-induced hypertension in pregnant rats: effect of chronic treatment with l-arginine

2001 ◽  
Vol 100 (6) ◽  
pp. 667-671 ◽  
Author(s):  
Eduardo PODJARNY ◽  
Michael BURSZTYN ◽  
Gloria RASHED ◽  
Sidney BENCHETRIT ◽  
Bernard KATZ ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Body Weight ◽  
Risk Factor ◽  
Chronic Treatment ◽  
Blood Pressure Response ◽  
Urinary Metabolites ◽  
Pregnant Rats ◽  
Hypertension In Pregnancy ◽  
Induced Hypertension ◽  
In Pregnancy

Recent studies have shown that maternal hyperinsulinaemia is a risk factor for the development of hypertension in pregnancy. Experimentally, pregnant rats with chronic exogenously induced hyperinsulinaemia (P-INS rats) have increased blood pressure at the end of gestation. This is associated with a blunted elevation of the excretion of the urinary metabolites of nitrate (UNOx). In the present study, we aimed to evaluate the mechanism(s) of the increase in blood pressure in this model. Four groups were studied: normal pregnant rats (P rats), P-INS rats, P-INS rats treated with l-arginine (2 g/l in the drinking water) (l-ARG rats) and hyperinsulinaemic virgin rats (V-INS rats). Systolic blood pressure (SBP), UNOx excretion (on ingestion of a controlled low-nitrate diet), urine noradrenaline (norepinephrine) and plasma endothelin levels were evaluated. Rats were killed on day 22 of pregnancy. Five P-INS rats were not killed at this time, in order to measure SBP 30 and 60 days after delivery. Fetal number and fetal body weight were evaluated. At the end of pregnancy, a 10±3% increase in SBP was found in P-INS rats, contrasting with a fall of -15±4% in P rats (P < 0.01). In the l-ARG group at the end of pregnancy, SBP values had fallen by -14±2%, to values comparable with those of P rats. The increase in UNOx excretion was 175±38% in P rats, 106±12% in l-ARG rats and 41±8% in P-INS rats (P < 0.01 compared with P and l-ARG groups). No differences were found in the urinary excretion of noradrenaline or in the plasma levels of endothelin-1 between the pregnant groups. Fetal number was similar in all groups, but fetal body weight was lower for P-INS rats compared with P and l-ARG rats. Thus the blood pressure response to l-arginine strongly suggests that a decrease in NO availability may be the main pathogenic mechanism involved in the development of hypertension in this model.

Cardiovascular risk profile of young hypertensive patients: the OPENJOVEN study

2011 ◽  
Vol 19 (3) ◽  
pp. 534-540 ◽  
Author(s):  
Nieves Martell-Claros ◽  
Alberto Galgo-Nafria
Keyword(s):  
Risk Factors ◽  
Blood Pressure ◽  
Primary Care ◽  
Risk Factor ◽  
Cardiovascular Risk ◽  
High Blood Pressure ◽  
Cardiovascular Risk Factor ◽  
European Society ◽  
Hypertensive Patients ◽  
Cardiovascular Profile

Background: Knowledge of the hypertensive patient’s characteristics is an important aspect to improve its clinical handling. Because of the burden that the patients of advanced age suppose in primary care, few data exist about the youngest patient's cardiovascular profile. Objective: To describe the cardiovascular profile of the young hypertensive patient (<55 years) in primary care in Spain. Design and methods: Cross-sectional multicentre study that was carried out in centres of primary care of the whole Spanish territory. At total of 2108 doctors participated and 6815 patients diagnosed with high blood pressure were included. We used a survey of risk factors, subclinical organ damage, and cardiovascular or renal established disease according to the European Society of Hypertension and the European Society of Cardiology 2007 guidelines to evaluate the cardiovascular risk. Results: Of the hypertensive patients, 5.8% did have not another cardiovascular risk factor (CVRF), 23.2% had one risk factor associated with high blood pressure, 32.8% two, 24.7% three, 11.3% four, and 2.3% had five risk factors. The most prevalent cardiovascular risk factor was dyslipidaemia, found in 80.4% (37.9% with treatment), followed by abdominal obesity, in 45.9% of the hypertensive patients. The prevalence of metabolic syndrome was 44.4%. The cardiovascular risk was average in 0.2% of the sample, low in 5%, moderate in 26.1%, high in 47.3%, and very high in 21.4%. Conclusions: Our study demonstrates that newly diagnosed young hypertensive patients have an intense association of CVRF and a high cardiovascular risk.

Sign in / Sign up

Export Citation Format

Share Document